Oftared Logo Banner enfermedades oculares
slide

Publicaciones volver

Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.

Tipo: Artículo
Autores: Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J.
Títuto Revista: Graefe's Archive for Clinical and Experimental Ophthalmology
Referencia:
Centro: 06 - UCM - IIORC
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1427-30. Epub 2009 Jul 21.

Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.

Source

Hospital Clínico Universitario San Carlos, Calle Profesor Martín Lagos s/n, Madrid, Spain. echejuan@yahoo.es

Abstract

BACKGROUND:

To report three cases of early choroidal neovascularization (CNV) bridging after ranibizumab treatment.

METHODS:

Three patients with two separated foci of CNV secondary to age-related macular degeneration (ARMD), pathologic myopia and multifocal choroiditis were treated with monthly injections of ranibizumab por a period of 3 months.

RESULTS:

All three cases showed early coalescence across the fovea of the two neovascular foci, already 1 month after the first ranibizumab injection. Best-corrected visual acuity (BCVA) decreased in the three cases more than 20 letters due to early foveal involvement.

CONCLUSIONS:

Two different foci of CNV show a great tendency to decrease patients' vision because of neovascular bridging with foveal implication.

PMID: 19621235 [PubMed - indexed for MEDLINE]